{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:56:04Z","timestamp":1790222164014,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The aim of this article is to provide a summary of the recent therapeutic advances and the latest research on outcome measures for juvenile dermatomyositis (JDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Several new international studies have developed consensus-based guidelines on diagnosis, outcome measures and treatment of JDM to standardize and improve patient care. Myositis-specific antibodies together with muscle biopsy histopathology may help the clinician to predict disease outcome. A newly developed MRI-based scoring system has been developed to standardize the use of MRI in assessing disease activity in JDM. New data regarding the efficacy and safety of rituximab, especially for skin disease, and cyclophosphamide in JDM support the use of these medications for severe refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>International network studies, new biomarkers and outcome measures have led to significant progress in understanding and managing the rare inflammatory myositis conditions such as JDM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000538","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T13:13:49Z","timestamp":1534511629000},"page":"650-654","source":"Crossref","is-referenced-by-count":16,"title":["Juvenile dermatomyositis: novel treatment approaches and outcomes"],"prefix":"10.1097","volume":"30","author":[{"given":"Giulia C.","family":"Varnier","sequence":"first","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa A.","family":"Pilkington","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust"},{"name":"Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health"},{"name":"NIHR GOSH Biomedical Research Centre (BRC), London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/B978-0-323-24145-8.00026-0","article-title":"Juvenile dermatomyositis","author":"Rider","year":"2016","journal-title":"Textbook of pediatric rheumatology"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","article-title":"The incidence of juvenile dermatomyositis: results from a nation-wide study","volume":"34","author":"Symmons","year":"1995","journal-title":"Br J Rheumatol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/acr.20280","article-title":"The Pediatric Rheumatology International Trials Organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"(Suppl 1)","key":"R7-20230901","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00228-010-0937-8","article-title":"Criteria to define response to therapy in paediatric rheumatic diseases","volume":"67","author":"Ruperto","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Rider","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2017-212141","article-title":"Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research","volume":"77","author":"McCann","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kex465","article-title":"Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample","volume":"57","author":"Silverberg","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Race, income and disease outcomes in juvenile dermatomyositis","volume":"184","author":"Philippi","year":"2017","journal-title":"J Pediatr"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3899\/jrheum.160997","article-title":"Submaximal exercise capacity in juvenile dermatomyositis after longterm disease: the contribution of muscle, lung, and heart involvement","volume":"44","author":"Berntsen","year":"2017","journal-title":"J Rheumatol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/acr.22867","article-title":"Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with juvenile dermatomyositis","volume":"68","author":"Campanilho-Marques","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/keh130","article-title":"Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis","volume":"43","author":"Maillard","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1148\/radiology.177.2.2217788","article-title":"Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease","volume":"177","author":"Park","year":"1990","journal-title":"Radiology"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12969-017-0154-4","article-title":"Muscle MRI at the time of questionable disease flares in juvenile dermatomyositis (JDM)","volume":"15","author":"Abdul-Aziz","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/ker262","article-title":"Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system","volume":"50","author":"Davis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R27-20230901","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key144","article-title":"Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis","author":"Thyoka","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/art.40395","article-title":"The Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans","volume":"70","author":"Ringold","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","article-title":"Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature","volume":"15","author":"Binns","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","article-title":"Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America","volume":"15","author":"Spencer","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0000000000000430","article-title":"A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab","volume":"23","author":"Montoya","year":"2017","journal-title":"J Clin Rheumatol"},{"issue":"(Suppl 2)","key":"R39-20230901","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/annrheumdis-2016-eular.5062","article-title":"OP0221 efficacy and safety of tumour necrosis factor-alpha antagonists in a large cohort of juvenile dermatomyositis patients","volume":"75","author":"Campanilho-Marques","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomised, double blind, placebo-control trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Shiffenbouer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tiarnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody positive amyophatic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002281-201811000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:56:29Z","timestamp":1786038989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201811000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000538","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}